- Tempus | AI-enabled precision medicine
Tempus has built the world’s largest library of clinical molecular data and an operating system to make that data accessible and useful, starting with cancer
- Tempus AI - Wikipedia
Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM " [6][7]
- Tempus AIs Data Business Is Expanding and Adding to Revenues: Heres . . .
Tempus AI ’s ( TEM Quick Quote TEM - Free Report) third-quarter 2025 results highlight the growing strategic importance of its Insights and Data Services business, which is emerging as a high
- Tempus | SoftBank Group Corp.
Launched in the United States in 2015, Tempus is now one of the largest sequencers of cancer patients in the world Having built its platform for oncology, it has expanded to neuropsychiatry, cardiology, infectious disease, and radiology
- Tempus AI (TEM): Assessing Valuation Following Analyst Optimism on . . .
Tempus AI (TEM) is drawing new attention after analysts highlighted strong momentum from its Ambry acquisition, advances in rare disease testing, and a new collaboration focused on precision medicine Investors are watching closely as these factors develop See our latest analysis for Tempus AI Tempus AI’s share price has surged more than 127% year to date as interest in healthcare
- What Does Tempus AI Actually Do? Unveiling the AI Revolution in . . .
In 2015, with a vision to revolutionize how doctors use data in clinical settings, Lefkofsky established Tempus The initial aim was to create a system where doctors could access a comprehensive, real-time view of a patient's medical history, including genomic, clinical, and imaging data
- Cathie Wood’s Health Tech Bet: Why Analysts See Long-Term Upside in . . .
Tempus AI Inc (NASDAQ:TEM) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio As of the end of September 2025, Tempus holds the ninth largest position in Cathie Wood’s ARK
- Tempus - 2025 Company Profile Team - Tracxn
Tempus is a public company based in Chicago (United States), founded in 2015 by Eric Lefkofsky It operates as an AI-based precision medicine solutions for oncology
|